An interventional study of MiraBurst in Dysgeusia and Solid Tumor, sponsored by Case Comprehensive Cancer Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.
Sponsored by Case Comprehensive Cancer Center · Not applicable, Interventional, and Supportive care
This study is for people with a diagnosis of solid tumor cancer who are experiencing changes in taste perception due to cancer treatment. Changes in taste perception, also known as dysgeusia, is a frequent side effect of cancer treatment and can significantly impacts quality of life. These alterations may be temporary or, in some cases, permanent.
The purpose of this study is determine whether freeze dried miracle fruit, marketed as MiraBurst can improve taste perception in this group of people. Participants involved in this study will be asked to take one MiraBurst mini-square upto four times a day, prior to eating, for 90 days.
Cancer and the treatment of cancer can create many symptoms that impact people's lives. More than 90% of people with cancer have at least one symptom caused by their cancer or treatment. The most common symptoms are related to the gastrointestinal system. Change in sense of taste is the fourth most common symptom and may be described as "food not tasting the same as they use to, food tasting bland, everything tastes the same, or an unpleasant bitter or metallic taste." Change in taste can impact a person's quality of life, but there are not many options to treat this symptom.
The MiraBurst product used in this study comes from a berry fruit harvested in Ghana. The berries are freeze-dried into a powder and pressed into small, square pieces that each weigh 300 mg. The product is made from 100% pure miracle berry powder and has the same natural composition as the fresh berry. It contains no additives or preservatives. The berry is vegan, allergen-free, and gluten-free, and it has no known side effects. During processing, no substances are extracted from the berries except water. This product is not classified as a drug or a dietary supplement and does not contain any active or inactive ingredients. Because it is a pure berry powder, it does not go through a strict standardization process. Both the raw freeze-dried powder and the finished product (MiraBurst Mini Squares) are tested by third-party laboratories for microbial safety in both Ghana and the United States. The powder is also tested for heavy metals and goes through contaminant removal and metal detection during manufacturing. According to the manufacturer, the freeze-dried miracle berry powder is produced in a Good Manufacturing Practice (GMP)-compliant facility in Ghana. The manufacturing and packaging facilities for MiraBurst Mini Squares in the United States (Connecticut and New Jersey) are also GMP-compliant. There are no known interactions between this product and herbs or medications. The product is available over the counter and is commonly used several times a day, up to five times daily-before breakfast, snacks, lunch, and dinner.
Previous studies have shown that supplements made from the same miracle fruit can have promising effects for people with cancer. One pilot study in 2010 found that 30% of people who received miracle fruit for two weeks reported improvements in their taste perception. In another pilot study, all participants who received miracle fruit reported positive changes after two weeks. Participants reported that taste changes such as experiencing a sour or metallic taste improved and that foods tasted sweeter or more pleasant. Yet another study found these similar positive changes, while also finding that participants who received miracle berry also had a higher energy intake, increased fat-free mass, and improved quality of life compared to participants on placebo. Preclinical data on miracle berry extract indicate that it is relatively safe, with no significant toxicity reported. The active component in miracle berry, miraculin, is a glycoprotein that is rapidly and completely digested in the gastrointestinal (GI) tract. This makes systemic absorption and interaction with drug-metabolizing enzymes, such as CYP450 or MAO (monoamine oxidase), highly unlikely. Both in silico and in vitro analyses have demonstrated a low potential for allergenicity or cross-reactivity with other proteins.
This study seeks to confirm the promising and beneficial effects of miracle fruit, with a branded product (MiraBurst), which has appropriate manufacturing controls in place for quality consistency, on symptoms related to dysgeusia (alterations in taste perception).
52 studies on the registry are indexed under Dysgeusia; 12 are open to participants now.
This study's planned enrollment of 45 is close to the median of 49 across 28 interventional studies indexed under Dysgeusia.
Browse Dysgeusia studies →Case Comprehensive Cancer Center is the lead sponsor of 494 studies on the registry; 61 are open to participants now.
Of its 75 completed or terminated interventional studies of FDA-regulated products, 46 (61%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will consume one MiraBurst mini-square prior to each meal (up to four times per day) for a 90 day period.
Dietary Supplement: MiraBurst
Participants will consume one 300 milligram (mg) MiraBurst mini-square prior to each meal (up to four times per day) for a 90 day period.
Also known as: Freeze-Dried Miracle Fruit
Evaluate effect on taste perception
Taste changes will be assessed using the Chemotherapy-induced Taste Alteration Scale-English version (CiTAS-E) questionnaire. The CiTAS questionnaire is composed of 18 items. Six questions are answered on a 5-point Likert scale from 1 (Taste normal) to 5 (Unable to taste at all). Twelve questions are answered on a 5-point Likert scale from 1 (No) to 5 (Very). The items are divided into three dimensions: 1) quantitative changes in the perception of flavors (hypogeusia, ageusia), 2) qualitative changes in the perception of flavors (i.e., heterogeusia, cacogeusia), and 3) problems related to nutrition (i.e., difficulty in eating hot or fat foods). CITAS questionnaire does not include open-ended qualitative questions. They are closed ended questions which participants rate. Higher scores indicate worse symptoms.
Time frame: Baseline (Day 1), Day 7
Evaluate effect on taste perception
Taste changes will be assessed using the Chemotherapy-induced Taste Alteration Scale-English version (CiTAS-E) questionnaire. The CiTAS questionnaire is composed of 18 items. Six questions are answered on a 5-point Likert scale from 1 (Taste normal) to 5 (Unable to taste at all). Twelve questions are answered on a 5-point Likert scale from 1 (No) to 5 (Very). The items are divided into three dimensions: 1) quantitative changes in the perception of flavors (hypogeusia, ageusia), 2) qualitative changes in the perception of flavors (i.e., heterogeusia, cacogeusia), and 3) problems related to nutrition (i.e., difficulty in eating hot or fat foods). CITAS questionnaire does not include open-ended qualitative questions. They are closed ended questions which participants rate. Higher scores indicate worse symptoms.
Time frame: Baseline (Day 1), Day 28
Evaluate effect on taste perception
Taste changes will be assessed using the Chemotherapy-induced Taste Alteration Scale-English version (CiTAS-E) questionnaire. The CiTAS questionnaire is composed of 18 items. Six questions are answered on a 5-point Likert scale from 1 (Taste normal) to 5 (Unable to taste at all). Twelve questions are answered on a 5-point Likert scale from 1 (No) to 5 (Very). The items are divided into three dimensions: 1) quantitative changes in the perception of flavors (hypogeusia, ageusia), 2) qualitative changes in the perception of flavors (i.e., heterogeusia, cacogeusia), and 3) problems related to nutrition (i.e., difficulty in eating hot or fat foods). CITAS questionnaire does not include open-ended qualitative questions. They are closed ended questions which participants rate. Higher scores indicate worse symptoms.
Time frame: Baseline (Day 1), Day 90
Evaluate effect on taste perception
Taste changes will be assessed using the Chemotherapy-induced Taste Alteration Scale-English version (CiTAS-E) questionnaire. The CiTAS questionnaire is composed of 18 items. Six questions are answered on a 5-point Likert scale from 1 (Taste normal) to 5 (Unable to taste at all). Twelve questions are answered on a 5-point Likert scale from 1 (No) to 5 (Very). The items are divided into three dimensions: 1) quantitative changes in the perception of flavors (hypogeusia, ageusia), 2) qualitative changes in the perception of flavors (i.e., heterogeusia, cacogeusia), and 3) problems related to nutrition (i.e., difficulty in eating hot or fat foods). CITAS questionnaire does not include open-ended qualitative questions. They are closed ended questions which participants rate. Higher scores indicate worse symptoms.
Time frame: Baseline (Day 1), Day 120
Evaluate effect on weight
Change in weight will be quantified as an absolute number change from baseline (in pounds (lbs)), as well as a percent change from baseline.
Time frame: Baseline (Day 1), Day 7
Evaluate effect on weight
Change in weight will be quantified as an absolute number change from baseline (in pounds (lbs)), as well as a percent change from baseline.
Time frame: Baseline (Day 1), Day 28
Evaluate effect on weight
Change in weight will be quantified as an absolute number change from baseline (in pounds (lbs)), as well as a percent change from baseline.
Time frame: Baseline (Day 1), Day 90
Evaluate effect on weight
Change in weight will be quantified as an absolute number change from baseline (in pounds (lbs)), as well as a percent change from baseline.
Time frame: Baseline (Day 1), Day 120
Evaluate effect on quality of life
Quality of Life will be assessed using the FAACT (functional assessment of anorexia/cachexia therapy) questionnaire. The FAACT questionnaire contains 40 items that measure four primary domains of global QoL along with specific anorexia/cachexia-related QoL issues. Physical well-being, social/family well-being, emotional well-being, and functional well-being comprise the four core measures of QoL, with an additional 12-item subscale evaluation of nutritional QoL. Items are answered on a 5-point Likert scale from 0 (Not at all) to 4 (Very much). The global scores are calculated by summing the scores of the five individual QoL domains; higher scores indicate better quality of life.
Time frame: Baseline (Day 1), Day 7
Evaluate effect on quality of life
Quality of Life will be assessed using the FAACT (functional assessment of anorexia/cachexia therapy) questionnaire. The FAACT questionnaire contains 40 items that measure four primary domains of global QoL along with specific anorexia/cachexia-related QoL issues. Physical well-being, social/family well-being, emotional well-being, and functional well-being comprise the four core measures of QoL, with an additional 12-item subscale evaluation of nutritional QoL. Items are answered on a 5-point Likert scale from 0 (Not at all) to 4 (Very much). The global scores are calculated by summing the scores of the five individual QoL domains; higher scores indicate better quality of life.
Time frame: Baseline (Day 1), Day 28
Evaluate effect on quality of life
Quality of Life will be assessed using the FAACT (functional assessment of anorexia/cachexia therapy) questionnaire. The FAACT questionnaire contains 40 items that measure four primary domains of global QoL along with specific anorexia/cachexia-related QoL issues. Physical well-being, social/family well-being, emotional well-being, and functional well-being comprise the four core measures of QoL, with an additional 12-item subscale evaluation of nutritional QoL. Items are answered on a 5-point Likert scale from 0 (Not at all) to 4 (Very much). The global scores are calculated by summing the scores of the five individual QoL domains; higher scores indicate better quality of life.
Time frame: Baseline (Day 1), Day 90
Evaluate effect on quality of life
Quality of Life will be assessed using the FAACT (functional assessment of anorexia/cachexia therapy) questionnaire. The FAACT questionnaire contains 40 items that measure four primary domains of global QoL along with specific anorexia/cachexia-related QoL issues. Physical well-being, social/family well-being, emotional well-being, and functional well-being comprise the four core measures of QoL, with an additional 12-item subscale evaluation of nutritional QoL. Items are answered on a 5-point Likert scale from 0 (Not at all) to 4 (Very much). The global scores are calculated by summing the scores of the five individual QoL domains; higher scores indicate better quality of life.
Time frame: Baseline (Day 1), Day 120
Plan to share: No
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Case Comprehensive Cancer Center →